细胞毒性肿瘤浸润性T淋巴细胞影响切除后胰腺导管腺癌的结局
在CONKO-001研究辅助吉西他滨治疗组与未治疗对照组共165例切除胰腺导管腺癌患者中,用组织芯片免疫组化检测CD3、CD8、CD103阳性T淋巴细胞。高数量CD8阳性淋巴细胞与更长无病生存和总生存显著独立相关;CD103阳性淋巴细胞中上皮内与总比值高者生存更差,但CD103总数或上皮内CD103阳性淋巴细胞数无此关联。作者认为T淋巴细胞亚群可能具有预后价值,但需标准化和进一步研究验证。
要点
- 低CD8阳性瘤内淋巴细胞(≤42/1mm组织芯)中位DFS/OS为7.4/18.1个月,高数量(>42/1mm)为12.7/25.2个月(p=0.008/0.020;HR 0.62/0.65)。
- CD103阳性淋巴细胞中上皮内与总比值>0.3者中位DFS/OS为5.9/15.7个月,≤0.3者为11.6/24.7个月(p=0.022/0.009)。
- CD103阳性淋巴细胞总数及CD103阳性上皮内淋巴细胞数与DFS/OS无显著关联。
核心结论
- T淋巴细胞亚群在可切除胰腺导管腺癌中可能具有预后价值,但需标准化和进一步研究验证。
研究设计与样本
- CONKO-001研究队列中165例切除胰腺导管腺癌患者,分辅助吉西他滨治疗组与未治疗对照组,用组织芯片免疫组化检测CD3、CD8和CD103。
主要发现
- 高数量CD8阳性淋巴细胞与更长DFS和OS显著独立相关。
- 低CD8阳性瘤内淋巴细胞(≤42/1mm组织芯)中位DFS/OS为7.4/18.1个月,高数量(>42/1mm)为12.7/25.2个月(p=0.008/0.020;HR 0.62/0.65)。
- CD103阳性淋巴细胞中上皮内与总比值与改善的DFS和OS显著相关(p=0.022/0.009),但CD103阳性淋巴细胞总数或CD103阳性上皮内淋巴细胞数无显著关联。
- 比值>0.3者中位DFS/OS为5.9/15.7个月,比值≤0.3者为11.6/24.7个月。
关键数值与推荐
- CD8阳性瘤内淋巴细胞低数量阈值≤42/1mm组织芯,高数量阈值>42/1mm组织芯。
- CD103阳性淋巴细胞上皮内与总比值高阈值>0.3,低阈值≤0.3。
局限性
- 原文结论指出需标准化和进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We studied the prognostic effect of CD3-, CD8- and CD103-positive T lymphocytes in a cohort of 165 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the treatment group (adjuvant gemcitabine) and the untreated control group of the CONKO-001 study. METHODS: Immunohistochemical stainings on tissue microarrays (TMAs) against CD3, CD8 and CD103 were performed according to standard procedures. RESULTS: A high number of CD8-positive lymphocytes were significantly and independently associated with longer disease-free survival (DFS) and overall survival (OS) in the overall study population. Median DFS/OS were 7.4/18.1 months for patients with a low number of CD8-positive intratumoural lymphocytes (≤42 per 1 mm tissue core) and 12.7/25.2 months for patients with high numbers (>42 per 1-mm tissue core; p = 0.008/0.020; HR 0.62/0.65). The ratio of intraepithelial to total CD103-positive lymphocytes, but not total numbers of CD103-positive lymphocytes or CD103-positive intraepithelial lymphocytes, was associated with significantly improved DFS and OS in the overall study population (p = 0.022/0.009). Median DFS/OS was 5.9/15.7 for patients with a ratio of intraepithelial to total CD103-positive intratumoural lymphocytes higher than 0.3 and 11.6/24.7 for patients with a lower ratio. CONCLUSION: T-lymphocyte subpopulations might be prognostic in resectable PDAC but need standardization and verification by further studies.
引用
- Lohneis P, Sinn M, Bischoff S, et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer. 2017. PMID: 28772128. doi:10.1016/j.ejca.2017.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。